European Patent Granted for ZyVersa Therapeutics' Lead Asset

Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including diabetic

Related Keywords

Alessia Fornoni , Casey Mcdonald , Stephenc Glover , Dave Schemelia , Peggy Harold Katz Drug Discovery Center , University Of Miami , Securities Exchange , Zyversa Therapeutics Inc , European Patent Office , Wolf Research , Katz Family Division Of Nephrology Hypertension , Nasdaq , Cholesterol Efflux Mediator , Versa Therapeutics , Patent Number , Katz Professor , Katz Family Division , Harold Katz Drug Discovery Center , Efflux Mediator , Zyversa Therapeutics , Securities Exchange Act , Private Securities Litigation Reform Act ,